Capacity Bio

Executive Summary

Capacity Bio is a private biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company is developing a first-in-class therapeutic platform targeting mitophagy, the cellular process responsible for clearing dysfunctional mitochondria. By leveraging this novel approach, Capacity Bio aims to address mitochondrial dysfunction, which is implicated in a broad range of diseases including neurodegeneration, metabolic disorders, and aging. In parallel, the company is building an advanced analytical toolkit to characterize mitochondrial biology, which may enable deeper insights into disease mechanisms and drug responses. Capacity Bio operates at the intersection of nanotechnology, RNA and gene therapy, and small molecules, reflecting a multi-modal strategy to modulate mitophagy pathways. The company is currently in the pre-clinical stage and is privately held with no disclosed funding rounds or valuation.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Announcement60% success
• H1 2027Preclinical Proof-of-Concept Data Release40% success
• Q2 2027Initiation of IND-Enabling Studies35% success